|
|
|
| From conventional two-stage hepatectomy to ALPPS: Fifteen years of experience in a hepatobiliary surgery unit |
| Javier Maupoey Ibanez a , ∗, Eva Maria Montalva Oron a , Andrea Bosca Robledo a , Alonso Camacho Ramirez a , Ana Hernando Sanz a , Pablo Granero Castro a , Alberto Alegre Delgado b , Rafael Lopez-Andujar a |
a Hepatobiliary Surgery and Transplant Unit, La Fe University and Polytechnic Hospital, Valencia, Spain
b Department of Radiology, La Fe University and Polytechnic Hospital, Valencia, Spain
∗ Corresponding author.
E-mail address: javiermaupoey@gmail.com (J. Maupoey Ibáñez). |
|
|
|
Abstract Background: Hepatectomy in patients with large tumor load may result in postoperative liver failure and associated complications due to excessive liver parenchyma removal. Conventional two-stage hep- atectomy (TSH) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique are possible solutions to this problem. Colorectal liver metastases (CRLM) is the most frequent indication, and there is a need to assess outcomes for both techniques to improve surgical and long-term oncological outcomes in these patients.
Methods: A single-center retrospective study was designed to compare TSH with ALPPS in patients with initially unresectable bilateral liver tumors between January 2005 and January 2020. ALPPS was performed from January 2012 onwards as the technique of choice. Long-term overall survival (OS) and disease-free survival (DFS) were evaluated as primary outcome in CRLM patients. Postoperative morbidity, mortality and liver growth in all patients were also evaluated.
Results: A total of 38 staged hepatectomies were performed: 17 TSH and 21 ALPPS. Complete resection rate was 76.5% ( n = 13) in the TSH group and 85.7% ( n = 18) in the ALPPS group ( P = 0.426). Overall major morbidity (Clavien-Dindo ≥3a) (stage 1 + stage 2) was 41.2% ( n = 7) in TSH and 33.3% ( n = 7) in ALPPS patients ( P = 0.389), and perioperative 90-day mortalities were 11.8% ( n = 2) vs. 19.0% ( n = 4) in each group, respectively ( P = 0.654). Intention-to-treat OS rates at 1 and 5 years in CRLM patients for TSH ( n = 15) were 80% and 33%, and for ALPPS ( n = 17) 76% and 35%, respectively. DFS rates at 1 and 5 years were 36% and 27% in the TSH group vs. 33% and 27% in the ALPPS group, respectively.
Conclusions: ALPPS is an effective alternative to TSH in bilateral affecting liver tumors, allowing higher resection rate, but patients must be carefully selected. In CRLM patients similar long-term OS and DFS can be achieved with both techniques.
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
